跳至主要内容
临床试验/NCT01310985
NCT01310985已完成不适用

A Pilot Trial of Pre-Operative Chemoradiotherapy Using Capecitabine (Xelodaâ), External Beam Radiation and Cetuximab (Erbitux®) Followed by Definitive Surgery in Patients With Localized (Non-Metastatic) Rectal Cancer

King Faisal Specialist Hospital & Research Center1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2008年3月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
15
试验地点
1
主要终点
Evaluate the safety of pre-operative concurrent chemotherapy with capacitabine (Xeloda), weekly cetuximab (Erbitux), and external beam radiation.

研究概览

简要总结

A Pilot Trial of Pre-Operative Chemoradiotherapy Using Capecitabine (Xelodaâ), External Beam Radiation and Cetuximab (Erbitux®) Followed by Definitive Surgery in Patients With Localized (Non-Metastatic) Rectal Cancer

详细描述

Its a pilot study of pre-op chemotherapy and RT utilizing CAPECITABINE, XRT and CETUXIMAB in pts with locally advanced rectal carcinoma.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Cross Sectional

入排标准

年龄范围
14 Years 至 85 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with Localized Non-Metastatic Rectal Cancer

排除标准

  • Patients with diagnosis other than Localized Non-Metastatic Rectal Cancer

结局指标

主要结局

Evaluate the safety of pre-operative concurrent chemotherapy with capacitabine (Xeloda), weekly cetuximab (Erbitux), and external beam radiation.

时间窗: For the duration of the experiment

次要结局

  • Evaluate efficacy of sphincter preserving surgery rate, local recurrence rate and the disease free and overall survival in patients.(For the duration of the experiment)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验